InvestorsHub Logo
Followers 48
Posts 3935
Boards Moderated 0
Alias Born 01/26/2011

Re: None

Monday, 02/18/2013 10:52:18 AM

Monday, February 18, 2013 10:52:18 AM

Post# of 345998
On Downplaying the Pancreatic results...

If CELG and/or Merck KGaA were potential partners with pancreatic cancer drugs that they've spent millions developing you probably wouldn't want to trumpet your results.

And for those asking about ECOG 2, PPHM expanded the pancreatic inclusion criteria toward the end of the study to include more sick patients because they were having trouble with enrollment. It was in a 2011 PR, just can't find it now. All IMO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News